Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 292, Issue 4, 2002, Pages 860-868

  Zhang, Lin ^a,b   Conejo Garcia, Jose Ramon ^a   Huang, Wei ^a   Mohamed Hadley, Alisha ^a   Yao, Weijia ^a   Benencia, Fabian ^a   Coukos, George ^a,b,d   Yang, Nuo ^c  

^a Center for Research on Reproduction and Women's Health   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Division of Gynecologic Oncology   (United States)

Author keywords

Glucose starvation; Isoform; mRNA expression; mRNA stability; Ovarian carcinoma; Real time PCR; Vascular endothelial growth factor

Indexed keywords

GLUCOSE; ISOPROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 120; VASCULOTROPIN 164; VASCULOTROPIN 188;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STRESS;

MURINAE;

EID: 0036297353     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2002.6710     Document Type: Article

References (48)

1. Vascular endothelial growth factor (VEGF) and its receptors
2. Angiogenesis in cancer and other diseases
3. The splice variants of vascular endothelial growth factor (VEGF) and their receptors
4. Vascular-specific growth factors and blood vessel formation
5. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences
6. Comparative expression of novel vascular endothelial growth factor/vascular permeability factor transcripts in skin, papillomas, and carcinomas of v-Ha-ras Tg. AC transgenic mice and FVB/N mice
7. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
8. Differential expression of VEGF isoforms in mouse during development and in the adult
9. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells
10. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
11. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
12. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
13. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
14. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
15. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF
16. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature
17. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma
18. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer
19. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma
20. Regulation of hypoxia-induced angiogenesis: A chaperone escorts VEGF to the dance
21. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
22. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
23. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1 alpha → hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors
24. Oxygen supply and oxygen-dependent gene expression in differentiating embryonic stem cells
25. Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury
26. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
27. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
28. A novel method for real time quantitative RT-PCR
29. Real time quantitative PCR
30. Development of a syngeneic mouse model for events related to ovarian cancer
31. Human beta-defensin 4: A novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity
32. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity: Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction
33. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells
34. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements
35. A genomic view of alternative splicing
36. Genetic and biochemical analysis of alternative RNA splicing
37. Alternative splicing and genome complexity
38. Vascular endothelial growth factor in ovarian cancer
39. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization
40. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice
41. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors
42. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms
43. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma
44. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
45. 2 homeostasis by hypoxia-inducible factor 1 alpha
46. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR
47. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia
48. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport